Compare Johnson & Johnson (JNJ) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Raymond James Financial, Inc. — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while Raymond James Financial, Inc. trades at $157.94 (market cap $30.51B). The key difference: Johnson & Johnson is far larger — about 20.3× Raymond James Financial, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Raymond James Financial, Inc. for 75 Days on average.
| JNJ | RJF | |
|---|---|---|
Market Cap | $618.09B | $30.51B |
Volume | 6,050,983 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $278.43 | $181.18 |
52-Week Low | $186.00 | $140.89 |
Typical Hold Time | 129 Days | 75 Days |
Enterprise Value | $646.37B | $24.37B |
Dividend Yield | 2.09% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
RJF trades at $158.28, up 0.63% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 exceeding expectations. Revenue grew to $13.84B in 2025, and net income margin stands at 15.37%. Recent news highlights executive leadership changes and a declared dividend of $0.54 per share payable in October 2026.
The outlook is mixed: analyst consensus is a 'Hold' with a $184 price target, implying potential upside, but technical indicators signal near-term caution. Key risks include rising expenses and market volatility, while growth drivers include wealth management expansion and investment banking recovery. The stock presents a balanced opportunity with solid fundamentals offset by technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
